Surrozen reports Q2 2026 results, plans SZN-8141 IND filing by Q3 end

Surrozen, Inc. (Nasdaq: SRZN) reported financial results for the second quarter ended June 30, 2026 and gave a pipeline update on August 6, 2026. The company said it plans to file an IND application for SZN-8141 by the end of the third quarter of 2026 and to begin a Phase 1b/2a study called DUET in diabetic macular edema patients by year-end 2026.¹

The DUET study will have two parts. Part 1 is an open-label Phase 1b single-ascending-dose portion enrolling both treatment-naive and previously treated DME patients, followed by a randomized, double-masked Phase 2a dose-expansion portion in treatment-naive DME patients in Part 2.¹ In Part 1, patients will get one intravitreal injection of SZN-8141 and be monitored for roughly three months for safety, tolerability, pharmacokinetics, immunogenicity, and exploratory retinal measures.¹ Part 2 is designed to test two dose levels of SZN-8141 against Vabysmo (faricimab-svoa) in about 60 treatment-naive DME patients, who would receive three monthly doses followed by a four-month follow-up to assess how long the effect lasts.¹ The company expects to start DUET by year-end 2026, with initial data anticipated in the second half of 2027.¹

On intellectual property, the U.S. Patent Trial and Appeal Board denied institution of a post-grant review petition from Merck challenging Surrozen's U.S. Patent No. 12,297,278 in July 2026, finding the petition failed to show a reasonable likelihood of prevailing on the challenged claims.¹ Separately, Boehringer Ingelheim triggered a development milestone under its SZN-413 license agreement in June 2026 after starting a Phase 1 study.¹

On cash, Surrozen held $102.0 million in cash and cash equivalents as of June 30, 2026, down from $106.9 million at the end of the first quarter.¹ Net income for the quarter was $50.2 million, which included $59.6 million in non-cash gains from changes in the fair value of tranche liability and warrant liabilities.¹